Press Release 2012

The Japan Patent Office has awarded Sabinsa Corporation, headquartered in East Windsor, New Jersey, a patent for the company's water-soluble form of naturally available diterpenes derived from Coleus forskolii. The patent covers both the method for solubilizing diterpenes using randomly methylated β-cyclodextrin molecules and applications thereof in glaucoma. Sabinsa will market the product under the name OcuFors®.

OcuFors® is another breakthrough from Sabinsa: it is the first naturally derived pharmaceutical product that has been approved by the Drug Controller General of India. The company is seeking approval as a drug for glaucoma treatment in several other countries.

OcuFors® has been found to be superior drug for treatment of open-angle glaucoma and reducing the intraocular pressure better than Timolol, a non-selective beta blocker used in glaucoma treatment.

Dr. Muhammed Majeed, Chairman & Founder of the Sami & Sabinsa group of companies, said, "The patented water-soluble forskolin solution exemplifies the stringent research, development, safety and efficacy standards that constitute the Sabinsa group’s forte."

This patent represents the 73rd in Sabinsa Corporation's robust global patent portfolio. 

    VISIT US

  • Sabinsa Canada Inc.
    1200 Aerowood Drive, Unit 32
    Mississauga, ON L4W 2S7
    Canada

  • +1 905-232-1242
  • +1 437-988-1663
  • info@sabinsa.ca

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US